Prognostic Factors for Multiple Sclerosi...

Interview with Colin P. Derdeyn, MD, author of Intravenous Argatroban or Eptifibatide in Patients Undergoing Mechanical Thrombectomy: A Subgroup Analysis of the MOST Randomized Clinical Trial. Hosted by Cynthia E. Armand, MD. Related Content: Intravenous Argatroban or Eptifibatid ... Show More

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 

Interview with Richard B. Lipton, MD, author of Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. Hosted by Cynthia E. Armand, MD. Related Content: Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressiv ... Show More

New medications for obesity, such as semaglutide and tirzepatide, are highly effective but can be associated with adverse effects that reduce adherence. Obesity expert and author Robert Kushner, MD, joins JAMA Deputy Editor Mary McDermott, MD, to discuss a recent JAMA Insights ar ... Show More

New weight-loss drugs have transformed care for people with obesity. In this Clinical Reviews podcast, Robert F. Kushner, MD, MS, of Northwestern University Feinberg School of Medicine joins JAMA Deputy Editor Mary McGrae McDermott, MD, to discuss prescribing these drugs to impro ... Show More

Join Dr. Chandra as she discusses the importance of understanding the risks of obesity and how we can address the disease during National Obesity Care Week. 

About 20% of adolescents in the US are living with obesity. Author Aaron S. Kelly, PhD, of the University of Minnesota Medical School joins JAMA Senior Editor Karen E. Lasser, MD, MPH, to discuss Obesity in Adolescents: A Review. Related Content: Obesity in Adolescents 

The rise in obesity and chronic disease over the years is alarming. Rather than genetics, it can be attributed to environmental and dietary changes, emphasizing the role of food quality over quantity. And while GLP-1 agonists like Ozempic may show some promise in addressing metab ... Show More

Join The Obesity Medicine Nutrition Course! Enter code POD15 at checkout for 15% off!Anti-obesity medications are everywhere—but they also come with new challenges. From rapid weight loss and side effects to TikTok-fueled supplement questions, patients on weight management medica ... Show More

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter dives back into the increasingly popular topic of GLP-1 agonists, such as Ozempic and Mounjaro, which ... Show More

This is an “ask me anything” (AMA) episode with Dr. Stephan Guyenet, an expert in obesity neuroscience and eating behavior. This episode was originally published on Sigma Nutrition Premium. If you’re interested in subscribing to Sigma Nutrition Premium, then check all the details ... Show More

In this episode, respected neuroscientist and author Dr. Tara Swart joins Jake to uncover fascinating perspectives about the complex interplay between our brains and bodies. Tara sheds light on how our constant smartphone use impacts us both mentally and physically, and what we c ... Show More

Ozempic, Wegovy, and Mounjaro, are being called “miracle drugs” with users boasting about their fast results. Dr. Sanjay Gupta takes a deep dive into how they disrupted the entire weight loss industry and changed the conversation about obesity.  Learn more about your ad choices. ... Show More